Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance
Status:
Completed
Trial end date:
2021-04-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the pre, post, and follow up effects of a single
ZILRETTA knee injection vs a single CELESTONE SOLUSPAN knee injection on physiological
measure of self-reported quality of life, pain, physical function, and physical performance
in individuals with osteoarthritis (OA) knee pain. The Primary Investigator (PI) will recruit
20 symptomatic knee OA patients for this study. Patients will be randomized into one of two
treatment arms, Arm 1 (ZILRETTA injection) or Arm 2 (CELESTONE SOLUSPAN injection). Patients
in Arm 1 will receive a single 5 mL IV injection of 32 mg ZILRETTA into the affected knee
joint. Patients in Arm 2 will receive a 5ml IV injection of 6mg/ml CELESTONE SOLUSPAN into
the affected knee joint. Each study arm will include 10 patients. All data will be collected
prior to injection (baseline), as well as at 6-week (post 1) and 12-week follow-ups (post 2).
Patients will blinded to treatment arm until after they complete their 12-week follow up.